[First Second-class Protected Variety of Chinese Medicine]  [National Patent for Invention of New Drugs]

[National "Ninth Five-Year Plan" and "Tenth Five-Year Plan" Major Science and Technology Awards]

[Second Grade National New Medicine]  [National Key New Products]

[National 863 Science & Technology Project Award]  [National "863" Program]

[Indications]
Cardio-cerebral vascular diseases mainly associated with PAF
1. CHD, Stenocardia, ACS and AMI;
2. CI and Cerebral Circulation Insufficiency;
3. Antiplatelet aggregation therapy after coronary intervention operation;
4. Strengthen antiplatelet aggregation therapy (Combined with other antiplatelet medicines);
5. Intervention in resistance phenomenon of Aspirin and Clopidogrel;
6. Diabetic microvascular complications: nephropathy proteinuria, peripheral neuropathy and retinopathy;
7. Pulmonary heart disease with Hyperviscosity;
8. Ischemic retinopathy and sudden deafness.

[Adaptive Department]
Cardiology, Neurology, Endocrinology, Nephrology, Orthopedics, Hematology, Surgery, Ophthalmology, Gynecology, etc.